Stay updated with the latest lupin-limited news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on lupin-limited topics.
Bosch Ltd | Technology and services provider firm, has approved the acquisition of a 100% stake in Bosch Chassis Systems India for ₹9,068.68 crore from its group entities. Lupin | The pharma company has received USFDA approval for its Dapagliflozin and Metformin extended-release tablets in multiple strengths, boosting its US diabetes portfolio. Earnings | Tata Consultancy Services, Anand Rathi Wealth Ltd, and GM Breweries Ltd are set to report their Q4 results on April 9, with investors also ...Read More >
Lupin announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio and strengthen its presence in Europe. The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hyg ...Read More >
New Delhi [India], April 2 (ANI): Lupin Ltd. has completed the acquisition of VISUfarma B.V, a European pharmaceutical company focused on ophthalmology, the company said in an exchange filing on Thursday. Lupin said the acquisition is a "significant milestone" in its strategy to expand the speciality care portfolio and strengthen its presence in the European region. "The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry ...Read More >
New Delhi, Oct 9 (PTI) Drug firm Lupin on Thursday announced the launch of a strategic partnership programme aimed at expanding the reach of a long-acting injectable platform developed by its subsidiary, Nanomi BV. The platform, PrecisionSphere demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent US Food and Drug Administration (USFDA) approval for the first product developed with this platform. The company's partnership programme is designed ...Read More >
MUMBAI, India and NAPLES, Fla., Oct. 9, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of a strategic partnership program aimed at expanding the reach of PrecisionSphere™ - the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi B.V. (Nanomi). PrecisionSphere™ demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent Unit ...Read More >
Mumbai: Less than a month after Ozempic maker Novo Nordisk announced it is cutting its global workforce as part of a restructuring plan, the layoffs have hit Indian employees in Bengaluru. Junior- to mid-level employees across functions such as sales and marketing, as well as those in the company's global business services (GBS) hub, which works with its global teams, have been impacted, according to at least three people aware of the development. "At least 100-150 will be retrenched from the ...Read More >
New Delhi, Sep 26 (PTI) US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 is unlikely to have an immediate impact on Indian exports, as it will affect only patented and branded products, not generic medicines, pharma industry players said on Friday. Indian Pharmaceutical Alliance (IPA), which represents 23 leading Indian pharmaceutical firms, including Dr Reddy's Laboratories, Sun Pharma, Lupin and Zydus Lifesciences, noted that Trump' ...Read More >
New Delhi: US President Donald Trump's decision to impose 100% tariffs on branded and patented drug exports has shaken Indian pharmaceutical markets, despite most of India's $10 billion US sales being in generics. The uncertainty lies in whether complex generics and specialty medicines will be included, a move that could directly impact leading players like Sun Pharma, Dr. Reddy's, Cipla, Zydus Lifesciences, and others. Stocks Facing Highest Exposure Dr. Reddy's emerges as the most vulnerable, ...Read More >
New Delhi, Sep 26 (PTI) Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines. Reacting to the development, IPA Secretary General Sudarshan Jain said in a statement, "It is not applicable to generics medicines." Trump's statement refers to patented and branded products supplied to US, he added. In his post on social me ...Read More >
New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement. Lupin will be responsible for manufacturing the product and for regu ...Read More >
New Delhi [India], July 16 (ANI): The Indian government expressed regret on Tuesday over the reported demolition of the ancestral property of celebrated filmmaker and writer Satyajit Ray in Mymensingh, Bangladesh and expressed its willingness to extend cooperation in its restoration. "We note with profound regret that the ancestral property of noted filmmaker and litterateur Satyajit Ray in Mymensingh, Bangladesh, belonging to his grandfather and eminent litterateur, Upendra Kishor Ray Chowdhur ...Read More >
India Diabetes Market: By Type; By Treatment Type; By Doses Form; Route of Administration; By End User; By Distribution Channel; Supplier Landscape; 2025-2034 The India diabetes market attained a value of approximately INR 316.00 Billion in 2024. The market is projected to grow at a compound annual growth rate (CAGR) of 16.00% during the forecast period of 2025-2034, reaching an estimated value of around INR 1394.01 Billion by 2034. The rising prevalence of diabetes, driven by sedentary lifesty ...Read More >
NEW DELHI: In his latest salvo against US trading partners, US President Donald Trump threatened aggressive tariffs on drug imports, raising fresh concerns for the export-intensive domestic pharma sector. "Pharma is going to be tariffed at a very, very high rate, like 200%," Trump said late on July 8. Tariffs on pharmaceuticals would come into effect after a grace period of at least a year, he added. Domestic pharma stocks, including Sun Pharma, Aurobindo, and Lupin, were fairly resilient, closi ...Read More >
NEW DELHI: The Nifty Pharma index traded negative around 10:51AM(IST)on Wednesday in a weak market. Mankind Pharma Ltd.(up 1.71 per cent), Sun Pharmaceutical Industries Ltd.(up 0.69 per cent), Aurobindo Pharma Ltd.(up 0.63 per cent), Lupin Ltd.(up 0.48 per cent) and Laurus Labs Ltd.(up 0.41 per cent) were among the top gainers. Gland Pharma Ltd.(down 1.66 per cent), Torrent Pharmaceuticals Ltd.(down 1.29 per cent), Natco Pharma Ltd.(down 1.26 per cent), Cipla Ltd.(down 0.57 per cent) and Dr. R ...Read More >
NEW DELHI: The Nifty Pharma index closed on a positive note on Tuesday. Shares of Laurus Labs Ltd.(up 2.93 per cent), Gland Pharma Ltd.(up 2.43 per cent), Biocon Ltd.(up 1.92 per cent), Zydus Lifesciences Ltd.(up 1.27 per cent) and Lupin Ltd.(up 1.19 per cent) ended the day as top gainers in the pack. On the other hand, Abbott India Ltd.(down 2.82 per cent), Ajanta Pharma Ltd.(down 2.78 per cent), J B Chemicals & Pharmaceuticals Ltd.(down 2.01 per cent), Alkem Laboratories Ltd.(down 1.83 per c ...Read More >
Mumbai, February 4: The Indian stock market on Tuesday ended on a strong note with both the BSE Sensex and NSE Nifty closed with gains of more than1 per cent as investors closely monitored tariff-related developments in the United States. The Sensex, after touching the day's high of 78,658.59, settled at 78,583.81 with an increase of 1,397.07 points or 1.81 per cent from the previous close. Meanwhile, the Nifty ended at 23,739.25, up by 387.20 points or 1.62 per cent. The index traded within a ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.